All Articles
Site oversight of home nursing and mobile phlebotomy in decentralized trials
Home nursing visits and mobile phlebotomy have moved from pandemic-era experiments to rout...
Mahesh Upadrista
Risk-based quality management under ICH E6(R3): what sponsors need to understand
Clinical trial quality used to sit in a section. Under ICH E6(R3), it sits in the spine. T...
Deeksha Gitta
What Happens to Clinical Trial Data After a Study Ends
Clinical trials generate a large amount of information. Blood tests, questionnaires, medic...
Anish TeepireddyParticipants
What Happens to Clinical Trial Data After a Study Ends
Clinical trials generate a large amount of information. Blood tests, questionnaires, medic...
Anish Teepireddy
Adaptive clinical trials explained: how a study can change while it is running
The idea that a clinical trial can change while it is running surprises many people who ar...
Deeksha Gitta
Neurosurgery Awareness Month 2026: clinical trials, precision care, and how participation works
Neurosurgery is one of the most technically demanding fields in modern medicine, and it is...
Anish TeepireddySponsors
Risk-based quality management under ICH E6(R3): what sponsors need to understand
Clinical trial quality used to sit in a section. Under ICH E6(R3), it sits in the spine. T...
Deeksha Gitta
What ICH E6(R3) means for sponsors: quality by design from day one
The International Council for Harmonisation (a global body that aligns drug-regulation sta...
Mahesh Upadrista
Comparison groups built from data: a plain guide to synthetic control arms
Many clinical trials still need a comparison group, but a growing number of them build tha...
Anish TeepireddyResearch Sites
Site oversight of home nursing and mobile phlebotomy in decentralized trials
Home nursing visits and mobile phlebotomy have moved from pandemic-era experiments to rout...
Mahesh Upadrista
Hybrid clinical trial visits: how research sites decide what stays on-site and what goes remote
Hybrid designs are no longer an experiment for research sites to accommodate on the margin...
Vamshi Kantoju
What is continuous inspection readiness? A research site guide to eTMF audit-proofing
An inspector could arrive next quarter, next month, or with only a few days of notice. Res...
Anish TeepireddyCROs
Tokenization in clinical trials: how CROs link real-world data
Tokenization has moved from research curiosity to operational plumbing in the clinical tri...
Paramraj
Centralized statistical monitoring in clinical trials: what CROs need to build
Every clinical trial produces a running stream of data long before database lock. Case rep...
Paramraj
ICH E6(R3) and what changes for CRO quality management at scale
Clinical trial quality management is moving from a documentation exercise to an evidence e...
Swaroop ESDHealthcare Professionals (HCPs)
How to read a master protocol as a referring physician
A patient sits across from you with newly diagnosed advanced non-small cell lung cancer. H...
Paramraj
Placebos and synthetic control arms: how HCPs can explain modern trial designs to patients
Why the placebo conversation is the hardest one HCPs have about clinical trials When a pat...
Swaroop ESD
Home healthcare in clinical trials: what HCPs should know
What home healthcare in clinical trials means Home healthcare in clinical trials refers to...
Anish TeepireddyAdvocacy Groups
The Diversity Action Plan debate, explained for advocacy groups
A federal rule that was supposed to make clinical trials more representative of the people...
Swaroop ESD
Master protocols in rare disease research: why one study can serve many patients
A rare disease is one that affects fewer than 200,000 people in the United States. The Nat...
Anish Teepireddy
Synthetic control arms and placebos: what advocacy groups can teach their communities
Placebo fear is one of the most common reasons people turn down a clinical trial. Communit...
Paramraj